在患有晚期髓性甲状腺癌的患者中对塞尔珀卡提尼布的初级耐药性

Fabian Pitoia1, Pierpaolo Trimboli2,3, Erika Abelleira4

  • 1Division of Endocrinology, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina. fpitoia@intramed.net.

Endocrine
|May 27, 2024
PubMed
概括

对RET激酶抑制剂塞尔珀卡丁尼布的初级耐药性在晚期髓性甲状腺癌 (MTC) 中是罕见的. 本案例研究探讨了一名患有M918T RET突变的患者,该患者最初没有反应,突出了对抗性机制进一步研究的需要.

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K